Centessa Pharmaceuticals (NASDAQ:CNTA) Given Equal Weight Rating at Wells Fargo & Company

Wells Fargo & Company restated their equal weight rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a report published on Monday,Benzinga reports. They currently have a $42.00 price target on the stock, up from their previous price target of $35.00.

A number of other analysts also recently issued reports on the company. Leerink Partners cut Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and upped their price objective for the stock from $36.00 to $40.00 in a research report on Wednesday, April 1st. Stephens downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Chardan Capital reissued a “buy” rating and set a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. B. Riley Financial cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Truist Financial downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target for the company. in a report on Monday, April 13th. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $40.70.

Centessa Pharmaceuticals Price Performance

Shares of CNTA opened at $39.51 on Monday. The firm has a market capitalization of $6.11 billion, a price-to-earnings ratio of -26.88 and a beta of 1.25. The firm’s fifty day simple moving average is $30.47 and its 200-day simple moving average is $26.88. Centessa Pharmaceuticals has a twelve month low of $10.95 and a twelve month high of $40.26. The company has a current ratio of 8.57, a quick ratio of 8.57 and a debt-to-equity ratio of 0.21.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, March 31st. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). Equities analysts forecast that Centessa Pharmaceuticals will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the transaction, the insider owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. This trade represents a 52.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Karen M. Anderson sold 120,029 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $26.25, for a total value of $3,150,761.25. Following the sale, the insider owned 62,085 shares in the company, valued at $1,629,731.25. This trade represents a 65.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 349,073 shares of company stock worth $9,429,412 over the last 90 days. Corporate insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Foresite Capital Management VI LLC grew its position in shares of Centessa Pharmaceuticals by 4.8% during the third quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock worth $31,865,000 after acquiring an additional 60,640 shares during the last quarter. Royce & Associates LP acquired a new position in shares of Centessa Pharmaceuticals in the 3rd quarter valued at $5,999,000. Eagle Health Investments LP purchased a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at $2,500,000. Cinctive Capital Management LP purchased a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at $2,246,000. Finally, Avoro Capital Advisors LLC boosted its stake in Centessa Pharmaceuticals by 116.2% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after purchasing an additional 5,808,080 shares during the period. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.